Answers are grounded in this paper and cite their sources.
BACKGROUND: Ectopic pregnancy causes major maternal morbidity and mortality. Human Placental growth hormone shows a non-pulsatile secretion pattern and short serum half-life making it of major advantage compared to the standard marker human chorionic gonadotropin. OBJECTIVE: To evaluate the clinical implication of serum human placental growth hormone variant and immunohistochemistry as a possible biomarker for the course of ectopic pregnancy. PATIENTS AND METHODS: This is a cross sectional study carried out in the department of Obstetrics and Gynecology of Al- Yarmouk Teaching Hospital for the period from January 2020 to October 2020, It includes 50 pregnant women in first trimester with confirmed ectopic pregnancy, maternal serum β -human chorionic gonadotrophin titer was measured and human placental growth hormone variant level was analyzed for each patient using enzyme-linked immunosorbent assay and tissue specimen were taken from serum human placental growth hormone variant negative and positive cases and examined by immunohistochemistry. RESULTS: Serum human placental growth hormone variant was shown to be positive in 28 cases of ectopic pregnancy and negative in 22 cases, β-human chorionic gonadotropin levels were significantly higher in the serum of the patient with human placental growth hormone variant positive group (p-value = 0.001). Serum human placental growth hormone variant was positive in all specimens of cases examined by immunohistochemistry even in serum negative cases. CONCLUSION: Human Placental growth hormone was shown to be present both in serum and tissue of ectopic pregnancy patients. Its short half-life makes it of a great clinical advantage as a biomarker for ectopic pregnancy course and monitoring response to treatment.
No takes yet. Share an insight, caveat, or question.
Shaheed et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: